X
More than 60,000 patients use Brite
4.6 stars
Your health finally understandable with Brite
Enter email and you're done. No subscription, no credit card.
Search, tap and you're done. Over 3,400 medicines.
Check, remind, get an overview.
Sarah K., 34
I finally understand my therapy. The app reminds me, answers my questions — and I don't feel alone with it anymore.
Olanzapine is an atypical antipsychotic and one of the most effective medicines available for schizophrenia and for bipolar disorder. The price for that is an unfavourable metabolic profile: hardly any other substance in this group leads so often to weight gain, rising blood sugar and rising blood lipids. If you plan for that from the outset and have it checked regularly, the treatment becomes far easier to stay with.
See more detail.gif)
On olanzapine, regular checks of weight and metabolic values are part of the treatment. The reason: a rising fasting blood sugar and rising blood lipids cause no complaints for years. Without measurement you only notice them once they have turned into diabetes or a lipid metabolism disorder.²
| What | When | Why |
|---|---|---|
| Weight and BMI | Before starting, closely in the first three months, then over time | An early warning system — the steepest rise falls in the opening phase |
| Waist circumference | Before starting and over time | Abdominal fat matters more metabolically than body weight does |
| Fasting blood sugar, HbA1c where needed | Before starting, in the first few months, then regularly | Picks up a glucose metabolism disorder before the complaints appear |
| Blood lipids (cholesterol, triglycerides) | Before starting, after a few months, then over time | Triglycerides often rise most clearly |
| Blood pressure | Before starting and over time | Part of the overall cardiovascular picture |
| Blood count and liver values | Before starting and over time | Captures rare changes in the blood count and in liver values |
| Movement disorders | Clinical assessment regularly at appointments | Early recognition of restlessness, tremor or stiffness |
The intervals are set by the treating practice; the guideline and the SmPC agree in recommending a baseline measurement before treatment starts and closer checks during the first year. How to make sense of the findings is explained in the guide understanding blood values.
The commonest mistake in handling olanzapine is waiting: first see whether the weight rises, then react. That works badly, because losing weight is harder than preventing it. It makes more sense to start the supporting measures together with the first tablet.
These measures do not replace a medical decision. But they push the point at which a change becomes necessary a long way back.
| Combination | Consequence | What to do |
|---|---|---|
| Smoking (starting or stopping) | Tobacco smoke revs up the metabolising enzyme CYP1A2: smokers have lower levels, and after stopping smoking those levels rise markedly | Raise a planned attempt to stop beforehand — the dose may need adjusting |
| Strong CYP1A2 inhibitors (e.g. the antidepressant fluvoxamine, some antibiotics) | Olanzapine levels rise, with more sedation and more side effects | Combine only under medical supervision, often at a reduced dose |
| CYP1A2 inducers (e.g. carbamazepine) | Olanzapine levels fall and the effect can wear off | Watch the effect closely, have the dose reviewed medically |
| Benzodiazepines such as lorazepam | Increased sedation and a drop in blood pressure; particular caution if both substances are injected at the same time | Only sparingly, for a limited time and under medical supervision |
| Other sedating agents (sleeping tablets, opioids, sedating antihistamines) | Cumulative tiredness, impaired reactions | Look at the overall picture rather than each preparation on its own |
| Blood pressure lowering medicines | A stronger drop in blood pressure when standing up | Stand up slowly, check blood pressure while the dose is being settled |
| Parkinson's medicines (levodopa, dopamine agonists) | Mutual weakening of effect | Only after careful medical consideration |
| Alcohol | Markedly increased sedation and drop in blood pressure | Avoid while the dose is being settled; be cautious in general |
It is not the nicotine but the combustion products in tobacco smoke that speed up the breakdown via the liver enzyme CYP1A2. People who smoke need higher doses on average for the same blood level. The reverse also applies: stop smoking and you suddenly have more of the drug in your blood — on an unchanged tablet dose. The effect sets in within a few days to weeks and shows up as increasing tiredness or drowsiness.
So stopping smoking is a good decision, but it belongs in the consulting room beforehand — just like a hospital stay where smoking is not possible. Nicotine replacement products do not have this effect, because they contain no combustion products: if you switch from cigarettes to patches, you still get the rise in levels. You can check further combinations in the guide to drug interactions; on alcohol, the guide medications and alcohol is worth reading.
Olanzapine is licensed for the treatment of schizophrenia and of moderate to severe manic episodes; where the response is good, also to prevent further episodes in bipolar disorder.¹
Here olanzapine is a first-choice substance — not because it is the best tolerated, but because it is among the most effective and reliably lowers the relapse rate. The S3 guideline stresses that the choice should be made together with the person being treated, weighing efficacy and side effect profile openly.² Someone who puts a stable weight first will decide differently from someone who has reacted badly to movement disorders.
In acute mania olanzapine works quickly — the dampening component is wanted here, because it stabilises the sleep-wake rhythm. In relapse prevention the benefit has to be set against the metabolic risk, which acts over years. That is why long-term use is regularly reviewed to see whether the dose still fits.
Olanzapine is not an antidepressant. In depression it is used only in particular constellations, for instance in a severe episode with psychotic features — a specialist decision, not a standard application.
Antipsychotics do not work "as required" — their benefit comes from continuity, and stopping is a treatment step in its own right, one that can be planned.⁴ Two things need to be distinguished:
In practice the dose is therefore reduced step by step over weeks to months, supported by appointments at which early warning signs are discussed. A documented record of doses and symptoms then shows whether a deterioration really is connected with the reduction.
Pregnancy and breastfeeding. Olanzapine is among the best-studied antipsychotics in pregnancy; on current knowledge an increased risk of malformations has not been established. Points to note are an increased risk of gestational diabetes and adaptation problems in the newborn after use in the final third of pregnancy. An existing treatment is not stopped abruptly — an untreated relapse is usually the greater risk for mother and child. The assessment is made by the treating practice, with Embryotox providing the specialist basis.⁵ The guide medications during pregnancy gives you your bearings.
Older age. Olanzapine is broken down more slowly, the sedation is stronger, and the drop in blood pressure when standing up raises the risk of falls. Treatment therefore starts lower and is increased more cautiously; if you take several preparations, it is worth looking at polypharmacy.
Liver and kidneys. Breakdown happens mainly through the liver; with impaired liver function the dose is lower and liver values are monitored. What applies in general is set out under medications for kidney and liver disease.
No, you do not have to put up with it in silence. All that matters is the order: raise it first, then act. Bring your weight record with weekly values and your current laboratory results. From those it becomes clear whether supporting measures are enough, whether the dose can be adjusted or whether a change of substance makes sense. What you should on no account do: halve or skip the tablet to slow the weight gain — that risks a relapse.
In most cases yes. The strongest sedation is in the first few weeks. It helps to take the evening dose early enough — take the tablet at midnight and you will wake up correspondingly later. If the drowsiness is still pronounced after several weeks, it belongs in the consulting room: sometimes the dose is higher than necessary, sometimes several sedating medicines add up. Do not drive during this phase as long as the assessment is unclear.
That you are well is as a rule the result of the treatment — not proof that it is superfluous. After a first episode, continued treatment over a longer period is recommended, and after several episodes correspondingly longer. An attempt to stop is possible, but planned, slow and supported — with early warning signs agreed in advance and an emergency plan.
So the conversation runs on numbers rather than memories — and the decision is built on them.
